Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01)

archived

-Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), invites investigator-initiated research grant applications for studies examining the adverse metabolic effects (i.e., obesity and diabetes) of psychotropic medications in animal models and across the human lifespan (including pediatric, adult and geriatric populations). Applications responsive to this FOA should focus on 1) increasing the understanding of the nature, rates, and pathophysiology of adverse metabolic effects of psychotropic medications, 2) elucidating biomedical and psychosocial risk factors for the development of metabolic adverse effects of psychiatric therapeutics, and 3) develop interventions to prevent and/or mitigate metabolic adverse effects across the lifespan.  -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

High